At the time of writing, Exagen Inc [XGN] stock is trading at $11.54, up 4.53%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The XGN shares have gain 5.29% over the last week, with a monthly amount glided 23.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Exagen Inc [NASDAQ: XGN] stock has seen the most recent analyst activity on September 11, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $15. Previously, KeyBanc Capital Markets upgraded its rating to Overweight on July 30, 2025, and kept the price target unchanged to $12. On July 23, 2025, Craig Hallum initiated with a Buy rating and assigned a price target of $12 on the stock. KeyBanc Capital Markets downgraded its rating to a Sector Weight. Canaccord Genuity started tracking with a Buy rating for this stock on April 15, 2021, and assigned it a price target of $25. In a note dated November 10, 2020, KeyBanc Capital Markets initiated an Overweight rating and provided a target price of $32 on this stock.
For the past year, the stock price of Exagen Inc fluctuated between $2.38 and $11.27. Currently, Wall Street analysts expect the stock to reach $12.5 within the next 12 months. Exagen Inc [NASDAQ: XGN] shares were valued at $11.54 at the most recent close of the market. An investor can expect a potential return of 8.32% based on the average XGN price forecast.
Analyzing the XGN fundamentals
According to Exagen Inc [NASDAQ:XGN], the company’s sales were 58.86M for trailing twelve months, which represents an 14.19% jump. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -0.24%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -1.36 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Exagen Inc [NASDAQ:XGN] has a current ratio of 4.95. As well, the Quick Ratio is 4.59, while the Cash Ratio is 2.92. Considering the valuation of this stock, the price to sales ratio is 4.31, the price to book ratio is 12.07.
Transactions by insiders
Recent insider trading involved Black Jeffrey G., Chief Financial Officer, that happened on Sep 02 ’25 when 20466.0 shares were sold. 10% Owner, NMSIC Co-Investment Fund, L.P. completed a deal on Mar 25 ’25 to sell 0.35 million shares. Meanwhile, 10% Owner NMSIC Co-Investment Fund, L.P. sold 0.2 million shares on Nov 20 ’24.
